|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.73 USD | -2.54% |
|
-8.60% | -23.25% |
| May. 08 | Transcript : Dynavax Technologies Corporation, Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Posts Q1 Revenue $50.8M, vs. Street Est of $55M | MT |
Dynavax Technologies Corporation provided financial guidance for the full year 2023. For the year, the company expects HEPLISAV-B net product revenue between approximately $165 - $185 million.
| 1st Jan change | Capi. | |
|---|---|---|
| -23.25% | 1.4B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
DYNAVAX TECHNOLOGIES CORPORATION 